NasdaqGS:KRYSBiotechs
A Look At Krystal Biotech (KRYS) Valuation After Vyjuvek Powered Q1 2026 Earnings Beat
Why Krystal Biotech’s latest earnings are moving the stock
Krystal Biotech (KRYS) is back on investors’ radar after Q1 2026 earnings topped expectations, with Vyjuvek-driven revenue and recent FDA approval updates drawing fresh attention to the stock’s risk reward profile.
See our latest analysis for Krystal Biotech.
Beyond the earnings beat, Krystal Biotech’s share price has picked up momentum, with a 7 day share price return of 13.13% and a year to date share price return of 20.17%, while...